Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -68.4%. (2010–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $203878 | $243222 | $291434 | $305386 | $586560 | $1M | $1M | $639800 | $483560 | $1M | $2M |
| Enterprise Value | $-4245122 | $-4205778 | $952434 | $-3539614 | $-12663440 | $-8073670 | $-12888057 | $-5092200 | $-5484440 | $-27029367 | $-32443004 |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.01 | 0.01 | — | 0.33 | 0.23 | 0.12 | 0.17 | 0.04 | 0.05 | 0.05 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.4% | -68.4% | -179.9% | -1281.4% | -483.2% | -233.3% | -258.4% | -195.7% | -119.6% | -103.3% | -43.8% |
| ROA | -35.1% | -35.1% | -72.1% | -110.1% | -139.3% | -132.7% | -137.1% | -125.9% | -87.7% | -74.5% | -31.3% |
| ROIC | -55.4% | -55.4% | -172.5% | — | — | — | — | -676.8% | -202.4% | — | -546680.5% |
| ROCE | -52.2% | -52.2% | -142.3% | -2151.9% | -628.6% | -230.5% | -252.6% | -272.9% | -119.7% | -129.0% | -65.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.15 | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.16 | 0.03 | — | -7.40 | -1.69 | -1.50 | -1.49 | -0.45 | -1.41 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -18.28 | -18.28 | -80.11 | — | — | — | — | — | — | — | -2.98 |
Net cash position: cash ($5M) exceeds total debt ($754000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.44 | 0.44 | 0.15 | 0.95 | 1.15 | 1.91 | 2.79 | 1.88 | 5.33 | 3.19 | 3.90 |
| Quick Ratio | 0.44 | 0.44 | 0.15 | 0.95 | 1.15 | 1.91 | 2.79 | 2.07 | 5.98 | 3.19 | 3.90 |
| Cash Ratio | 0.42 | 0.42 | 0.13 | 0.84 | 1.10 | 1.54 | 2.69 | 1.05 | 1.94 | 3.11 | 3.77 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $21040 | $5972 | $2447 | $1560 | $1073 | $789 | $457 | $385 | $311 | $294 |
Imminent liquidity and dilution
Based on reported financial data, AKTX trades at a P/B ratio of 0.01, a valuation level that suggests the market is pricing in extreme execution risk and potential insolvency rather than the long-term clinical optionality of the company's dual-action complement inhibitor platform.
The current valuation multiple is significantly compressed compared to peers like Corvus Pharmaceuticals, indicating that investors are heavily discounting the firm's intangible assets. This suggests that the market views the current pipeline as having limited terminal value without a major capital injection or a strategic partnership to validate the clinical data.
As reported in recent financial statements, AKTX's ROIC has remained consistently negative, reaching -65.3% in 2026Q1, which underscores the firm's inability to generate productive returns on invested capital while it remains in a pre-revenue, high-expenditure clinical development phase.
The persistent decay in ROIC reflects the structural reality of a biotech firm that must continuously deploy capital into R&D without any offsetting revenue streams. Investors should monitor whether future clinical milestones can shift this trajectory, though current trends suggest that capital is being consumed rather than compounded.
According to recent SEC filings, AKTX's current ratio has deteriorated to 0.27 as of 2026Q1, reflecting a precarious liquidity position where available cash is insufficient to cover immediate short-term obligations, signaling a high risk of near-term insolvency without an urgent external capital infusion.
The rapid decline in the quick ratio from 0.95 in 2023Q4 to 0.27 in 2026Q1 highlights the accelerating depletion of the firm's cash reserves. This trend suggests that the company's ability to sustain its clinical trial operations is increasingly dependent on the timing and terms of future dilutive financing rounds.
As indicated by the company's pre-revenue status, the use of P/E or EV/EBITDA ratios is fundamentally misapplied to AKTX, as these metrics obscure the firm's true economic reality by ignoring the binary nature of clinical trial outcomes and the necessity of non-dilutive capital.
Analysts should instead focus on 'Cash Runway' and 'Net Cash Burn' as the primary indicators of business health, as traditional profitability ratios are currently meaningless. Relying on earnings-based multiples in this context may lead to a false sense of security or an inaccurate assessment of the firm's actual survival probability.
Includes 30+ ratios · 16 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AKTX stock.
Akari Therapeutics, Plc's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Akari Therapeutics, Plc's return on equity (ROE) is -68.4%. The historical average is -194.2%.
Based on historical data, Akari Therapeutics, Plc is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.